Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER-Cervical 1: Cemiplimab vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT03257267Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2017
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 14
01
Overview
Phase 3, randomised, open-label trial of cemiplimab in Cervical Cancer (CC) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Overall Survival and Overall Survival in the SCC Population. Started Sep 2017; status: completed.
02
Drugs
cemiplimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03257267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03257267.